中药ETF（560080）标的指数热门成分股多数回调：仁和药业回调超1%，众生药业、华润三九、东阿阿胶、片仔癀微跌；上涨方面，盘龙药业涨超1%，云 南白药微涨。 杠杆资金方面，融资客继续借道ETF布局"性价比"更高的中药大消费板块，仍以中药ETF（560080）为例，基金最新融资余额逼近8000万元，融资余额连续 冲高，昨日融资买入额超1200万元！（截至2025.9.16，来源：上交所） | 序号 | 代码 | 名称 | 涨跌幅 | 估算权重 | | --- | --- | --- | --- | --- | | 1 | 002317 | 众生药业 | -0.45% | 3.27% | | 2 | 000538 | 云南日药 | 0.48% | 10.57% | | 3 | 0009999 | 华润三九 | -0.62% | 4.72% | | 4 | 000423 | 东阿阿胶 | -0.19% | 5.16% | | 5 | 000650 | 仁和药业 | -1.63% | 1.82% | | 6 | 600436 | 片仔瘦 | -0.01% | 10.89% | | 7 | 600332 | 日云山 ...

此次战略合作，不仅是仁和药业推进品牌知识产权数字化与全球化运营的关键举措，亦是中国医药企业对新运营模式的重 要实践。未来，双方将重点围绕知识产权数字化、全球市场拓展、智能估值体系构建与数字生态平台建设四大维度展开深度合 作，为医药行业树立知识产权运营新范式。 本报讯 （记者矫月）近日，华检医疗控股有限公司（以下简称"华检医疗"）与仁和药业股份有限公司（以下简称"仁和药 业"）子公司仁和（深圳）国际营销有限公司（以下简称"仁和国际"）达成非处方药（OTC）知识产权战略全景合作协议。双 方计划共同构建OTC资产价值网络，携手打造全球医药数字资产新标杆。此次合作标志着仁和药业从传统制药企业向数字化医 药生态运营者的战略跃迁，凸显其在品牌知识产权数字化管理方面的前瞻布局。 目前，全球医药产业正经历"研发与运营"深度改革，行业长期存在"无形资产沉睡、跨境效率低下、估值逻辑单一"等核心 痛点。华检医疗作为聚焦医疗健康领域数字化的创新服务商，具备深厚的行业资源积累与领先的数字资产解决方案能力。仁和 药业作为中国OTC领域的知名医药企业，旗下拥有"妇炎洁""优卡丹""闪亮"等多个国民级品牌和丰富的OTC医药资源，现已实 现中 ...

今日（9.16），大盘全天走势分化，中药板块三连阴。全市场规模领先的中药ETF（560080）收跌0.18%，场内多数时间溢价，全天成交额超1.6亿元，环比 大举放量74%。资金面上，中药ETF（560080）已连续11天获净流入，合计"吸金"2.35亿元，最新规模超24亿元，基金份额再创上市以来新高！ 中药ETF（560080）标的指数热门成分股涨跌互现：仁和药业涨超5%，盘龙药业涨潮3%，以岭药业、达仁堂微涨；下跌方面，白云山、云南白药、片仔 癀、东阿阿胶微跌。消息面上，仁和药业与博奥晶方签署基于分子本草技术的中药及大健康产品开发框架协议，将使用包括AI技术在内的各类专业技术。 杠杆资金方面，融资客继续借道ETF布局"性价比"更高的中药大消费板块，仍以中药ETF（560080）为例，基金最新融资余额超7700万元，昨日融资买入额 超1000万元！（截至2025.9.15，来源：上交所） 此外，仁和药业Ulook智能脑机眼镜备受市场关注，公司回应称其原理是将相关功能芯片植入眼镜框中，检测使用者的脑电波，然后通过手机APP反馈使用 者的专注力、情绪、用眼等状况，帮助使用者进行眼部健康训练。目前，Ulook眼镜 ...

9月16日午间，华检医疗（01931.HK）发布公告，宣布与仁和药业（000650）全资子公司仁和国际达成 战略合作，共同于美国筹建全球首家专注于非处方药（OTC）垂直领域的现实世界资产（RWA）交易 所。 公告称，此次合作是华检医疗"ETHK链上金融生态战略"及"全球RWA交易所中所"商业模式成功落地的 关键第一步与标杆案例，旨在打造一个可规模复制的样板，验证该创新模式的可行性及巨大潜力。 根据合作协议，华检医疗与仁和国际将共同筹建并运营专注于OTC资产的RWA交易所，华检医疗旗下 ETHK Inc提供合规运营支持，华检数字产业发展（深圳）有限公司负责技术开发。双方的合作模式高 度互补，体现"产业龙头+技术基础设施"的深度融合。 对仁和药业而言，此次合作则是其全球化与数字化转型的战略延伸。仁和药业是中国OTC市场龙头企 业，旗下拥有"妇炎洁""优卡丹"等多个驰名商标，渠道网络覆盖全国。 值得一提的是，9月16日午后，仁和药业和华检医疗均出现快速拉升，截至发稿，仁和药业涨幅超过 5%。 近年来，受医保控费与行业竞争影响，仁和药业传统业务增长承压。半年报显示，公司今年上半年营收 同比下滑16.46%，净利润同比 ...

华检医疗 (01931.HK)宣布，集团与 仁和药业 (000650.SZ)间接全资附属公司仁和国际达成战略合作，双 方将共同创立全球范围内首个专注于非处方药(OTC)细分领域的现实世界资产(RWA)专业化交易平台。 该平台将严格遵循证券级标准进行设计与运营，致力于为OTC行业的知识产权、未来收益权、品牌价值 等无形资产以及实体产品权益，提供一个高效、透明、且合规的数字化交易与价值发现场所，填补全球 市场的关键空白。 此次与仁和药业的战略合作，标志着集团「ETHK」链上金融生态战略进入了规模化落地与价值实现的 新阶段，亦是其创新的「ETHK全球RWA交易?所中所」商业模式在全球舞台的首次重磅亮相与实践验 证。此举深刻体现了集团在「聚焦核心战略、实现规模化复制、构建差异化优势」上的卓越规划与执行 能力，彰显了集团致力于通过前沿创新技术与严谨的合规实践，构建一个真正开放、赋能、共荣的数字 金融新生态的决心。 据悉，仁和药业作为中国非处方药物(OTC)协会会长单位，不仅深度参与行业政策研讨与标准制定，更 凭藉其在中国OTC市场极具竞争力的稳固份额，持续引领产业发展方向。公司在OTC领域具备广泛的行 业号召力与话语权 ...

Core Viewpoint - Huajian Medical (01931) has announced a strategic partnership with Renhe Pharmaceutical (000650.SZ) to establish the world's first vertical RWA exchange focused on the OTC sector in the United States, marking a significant step in the implementation of its "ETHK blockchain financial ecosystem strategy" [1][2] Group 1: Strategic Collaboration - The collaboration with Renhe Pharmaceutical signifies a new phase in the large-scale implementation and value realization of the "ETHK" blockchain financial ecosystem strategy [1] - This partnership serves as a benchmark case for the innovative "ETHK global RWA exchange" business model, aiming to create a replicable model that validates the feasibility and potential of this innovation [1] Group 2: Vision and Mission - The company believes that the ultimate mission of financial technology is to serve the real economy and create inclusive value, which this collaboration exemplifies [2] - The goal is to empower classic national brands like Renhe Pharmaceutical to achieve digital transformation and promote successful ecological models across various industries, contributing to national industrial upgrades and the development of the digital economy [2] Group 3: Future Outlook - The board is confident that this strong alliance will generate significant synergies, positively impacting the strategic transformation and value reassessment of both companies [2] - The company aims to ensure the successful launch and stable operation of the world's first OTC RWA exchange through close collaboration with Renhe Pharmaceutical, leveraging both parties' resources [2]

Core Viewpoint - The strategic partnership between Huajian Medical and Renhe Pharmaceutical aims to establish the world's first vertical RWA exchange focused on the OTC sector in the United States, marking a significant step in Huajian's ETHK blockchain financial ecosystem strategy [1][2] Group 1: Strategic Collaboration - The collaboration with Renhe Pharmaceutical represents a key milestone in the implementation of Huajian's ETHK blockchain financial ecosystem strategy and the innovative "ETHK global RWA exchange" business model [1] - This partnership is intended to create a replicable model that validates the feasibility and potential of the innovative approach [1] Group 2: Commitment to Economic Development - Huajian Medical emphasizes that the ultimate mission of financial technology is to serve the real economy and create inclusive value, which this collaboration exemplifies [2] - The company aims to leverage technology to assist classic national brands like Renhe Pharmaceutical in their digital transformation, promoting successful ecological models across various industries [2] Group 3: Future Growth and Synergy - The board believes that this collaboration will generate significant synergies, positively impacting the strategic transformation and value reassessment of both companies [2] - Huajian Medical plans to work closely with Renhe Pharmaceutical to ensure the successful launch and stable operation of the world's first OTC RWA exchange, aiming for high standards and quality [2]

此次与仁和药业的战略合作，标志着集团「ETHK」链上金融生态战略进入了规模化落地与价值实现的 新阶段，亦是其创新的「ETHK全球RWA交易•所中所」商业模式在全球舞台的首次重磅亮相与实践验 证。此举深刻体现了集团在「聚焦核心战略、实现规模化复制、构建差异化优势」上的卓越规划与执行 能力，彰显了集团致力于通过前沿创新技术与严谨的合规实践，构建一个真正开放、赋能、共荣的数字 金融新生态的决心。 华检医疗坚信，金融科技的终极使命在于服务实体经济，创造普惠价值。此次合作正是对这一信念的生 动诠释。集团旨在通过科技赋能，助力仁和药业这样的经典民族品牌完成数字化跃迁，并将其成功的生 态模式推广至各行各业，最终服务于国家产业升级与数字经济发展的宏大叙事，践行我们「利国利民利 天下」的企业初心与终极愿景。我们期待，这座全球首创的OTCRWA交易所不仅能成为价值流通的平 台，更能成为全球创新健康资源与庞大中国市场需求之间的超级连接器，为提升人类健康福祉贡献一份 力量。 董事会深信，此次强强联合将产生巨大的协同效应，不仅对双方企业的战略转型与价值重估产生深远且 积极的推动，更将为集团未来可持续的业务增长与财务表现注入强劲动力。集 ...

Core Viewpoint - The strategic partnership between Huajian Medical and Renhe Pharmaceutical aims to establish the world's first specialized trading platform for over-the-counter (OTC) real-world assets (RWA), addressing a significant gap in the global market [1][2]. Group 1: Strategic Collaboration - The collaboration signifies a new phase in Huajian Medical's "ETHK" blockchain financial ecosystem strategy, marking the global debut of its innovative "ETHK Global RWA Exchange" business model [2]. - Renhe Pharmaceutical, as the president unit of the China OTC Association, plays a crucial role in industry policy discussions and standard-setting, leveraging its strong market position to lead the development of the OTC sector [1][2]. Group 2: Goals and Vision - The partnership reflects the commitment to create a transparent, efficient, and compliant digital trading platform for intangible assets and product rights in the OTC industry, ultimately serving the broader goal of enhancing the digital economy and national industrial upgrades [2]. - The collaboration is expected to generate significant synergies, driving strategic transformation and value reassessment for both companies, while ensuring the successful launch and operation of the OTC RWA exchange [3].

华检医疗公告，公司与仁和药业间接全资附属公司仁和国际达成战略合作，共同于美国筹建全球首家专 注于非处方药（OTC）领域的垂直RWA交易所。 ...